Investigating genetic factors in diseases affecting premature infants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
This study is trying to see if certain genes and biomarkers can help us understand why some premature babies are more likely to develop serious health issues like lung disease and infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1100 (estimated) |
| Sex | All |
| Sponsor | Medical College of Wisconsin Academic / other |
| Locations | 1 site (Milwaukee, Wisconsin) |
| Trial ID | NCT00710112 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between genetic variations and the susceptibility to chronic lung disease (CLD) and other complications in very low birth weight (VLBW) infants. It focuses on understanding how specific gene variants, particularly those related to toll-like receptors, may influence the risk of developing conditions such as necrotizing enterocolitis, sepsis, and intraventricular hemorrhage. Additionally, the study will assess whether certain biomarkers in serum can help identify infants at higher risk for these diseases. By examining the interplay of genetic factors and biomarkers, the research seeks to provide insights into the pathogenesis of these serious conditions in premature infants.
Who should consider this trial
Good fit: Ideal candidates for this study are infants born weighing less than 1500 grams.
Not a fit: Patients with congenital heart disease (other than patent ductus arteriosus) or major congenital anomalies of the GI tract, respiratory tract, or kidneys may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk assessment and targeted interventions for premature infants at risk of chronic lung disease and other complications.
How similar studies have performed: Previous studies have indicated a correlation between genetic variants and increased risk of chronic lung disease in premature infants, suggesting that this approach has potential based on existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Infants born weighing less than 1500 grams Exclusion Criteria: * Infants born with congenital heart disease (other than patent ductus arteriosus) * major congenital anomalies of the GI tract, respiratory tract, or kidneys
Where this trial is running
Milwaukee, Wisconsin
- Children's Wisconsin — Milwaukee, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: G. Ganesh Konduri, MD — Medical College of Wisconsin
- Study coordinator: G. Ganesh Konduri, MD
- Email: gkonduri@mcw.edu
- Phone: 414.266.6820
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.